SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...
ResMed RMD recently introduced its ultra-compact, full-face mask, AirFit F40, in the United States. The new offering provides the comfort of smaller masks without sacrificing performance to help ...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the ...
We maintain our USD 258 fair value estimate for narrow-moat ResMed, or AUD 40 per CDI at current exchange rates, following first-quarter fiscal 2024 results. Underlying EBIT of USD 319 million grew 4% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results